THOR-707 for Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Investigational Site Number-2003, Victoria, Australia
Cancer+2 More
THOR-707 - Drug
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether a drug may help treat cancer.

See full description

Eligible Conditions

  • Cancer
  • Metastasis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Cancer

Study Objectives

This trial is evaluating whether THOR-707 will improve 4 primary outcomes and 11 secondary outcomes in patients with Cancer. Measurement will happen over the course of Study Day 1 until the date of first documented progression or date of death from any cause, assessed up to 24 months.

Month 6
Percentage of subjects with no disease progression at 6 months post-treatment
Month 24
Progression-Free Survival (PFS) according to RECIST version 1.1
Day 29
Maximum Tolerated Dose (MTD)
Rate of Dose-Limiting Toxicities (DLTs)
Recommended Phase 2 Dose
Recommended Phase 2 Dose (RP2D)
Month 24
Overall Survival according to RECIST version 1.1
Month 24
Assess plasma concentration of THOR-707 at various timepoints
Assess presence of antibodies to THOR-707 at various timepoints
Disease Control Rate (DCR) according to RECIST version 1.1
Duration of Response (DOR) according to RECIST version 1.1
Immunophenotyping of peripheral blood at various timepoints
Immunophenotyping of tumor samples at various timepoints
Objective Response Rate (ORR) according to RECIST version 1.1
Time to Response (TTR) according to RECIST version 1.1

Trial Safety

Safety Progress

1 of 3

Other trials for Cancer

Trial Design

4 Treatment Groups

Cohort C-THOR-707 with checkpoint inhibitor and dose escalation
1 of 4
Cohort D-THOR-707 with anti-EGFR antibody and dose escalation
1 of 4
Cohort B-THOR-707 Monotherapy and Dose Escalation Q3W
1 of 4
Cohort A-THOR-707 Monotherapy and Dose Escalation Q2W
1 of 4
Experimental Treatment

This trial requires 300 total participants across 4 different treatment groups

This trial involves 4 different treatments. THOR-707 is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

Cohort C-THOR-707 with checkpoint inhibitor and dose escalationDose Escalation: TTHOR-707 will be administered in sequential ascending doses in combination with a checkpoint inhibitor via IV administration Q3W or every 6 weeks (Q6W) until unacceptable toxicity, disease progression, or withdrawal of consent.
Cohort D-THOR-707 with anti-EGFR antibody and dose escalationDose Escalation: THOR-707 will be administered in sequential ascending doses in combination with an anti-EGFR antibody via IV administration Q3W/QW (once-weekly) (respectively) until unacceptable toxicity, disease progression, or withdrawal of consent.
Cohort B-THOR-707 Monotherapy and Dose Escalation Q3W
Drug
Dose Escalation: THOR-707 will be administered in sequential ascending doses as a monotherapy via IV administration every 3 weeks (Q3W) until unacceptable toxicity, disease progression, or withdrawal of consent.
Cohort A-THOR-707 Monotherapy and Dose Escalation Q2W
Drug
Dose Escalation: THOR-707 will be administered in sequential ascending doses as a monotherapy via intravenous (IV) administration every 2 weeks (Q2W) until unacceptable toxicity, disease progression, or withdrawal of consent.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months after the end of treatment (eot)
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 6 months after the end of treatment (eot) for reporting.

Closest Location

Investigational Site Number-1004 - Sarasota, FL

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Patients with advanced and/or metastatic solid tumors that can be safely biopsied are eligible for this study show original
Patients who have received prior cancer therapy are allowed to continue treatment as long as they are tolerating it well and their cancer is responding show original
Premenopausal women and women less than 12 months after menopause who have a negative serum pregnancy test within 7 days prior to initiating study treatment are eligible for the study. show original
Male participants must agree not to donate or store sperm during the treatment period and for at least three months after their last dose of study treatment. show original
The patient has a measurable disease as defined by the RECIST v1.1 guidelines. show original
The fetus has a life expectancy of more than 12 weeks. show original
A patient has an ECOG performance status of 0 or 1 if they are considered to have a very good or good prognosis. show original
All participants who are not surgically sterile must agree to use a medically accepted form of birth control throughout the study and for at least three months after the last dose of study medication. show original
The patient has good cardiovascular, hematological, liver, and renal function. show original
Key

Patient Q&A Section

What are common treatments for cancer?

"Overall, the most commonly used treatments for cancer patients were surgery, radiation therapy, and chemotherapy. These were the least common on the list of treatments for other conditions, such as acute lymphocytic leukemia, but were among the first options when a cancer patient was asked for a possible treatment for it. Treatment for cancer is highly dependent on the type of cancer." - Anonymous Online Contributor

Unverified Answer

How many people get cancer a year in the United States?

"About 4.5 million new cases of cancer are diagnosed each year, making it the most common type of cancer in Americans each year. theme: cancer survivors' health status, cancer patients' mental health, and primary care physicians' attitudes towards patients with cancer, survivorship and quality of life." - Anonymous Online Contributor

Unverified Answer

What are the signs of cancer?

"Cancer may have many features: it appears slowly, frequently produces various signs and symptoms, and can be fatal without proper examination and tests. To help you understand cancer, try to imagine the signs of it.\n" - Anonymous Online Contributor

Unverified Answer

What causes cancer?

"Cancer is in fact a heterogeneous group of malignant neoplasms. This complexity is reflected in our efforts to select the most commonly used diagnostic techniques. It is not enough to simply state that cancer is "caused" by some environmental and genetic factors, and other factors, for example, lifestyle choices, play an important role in the development of the majority of the neoplasms. All of the factors mentioned above should be considered together to arrive at an integrated concept of carcinogenesis. In this way, the term 'etiology' of cancer can be expanded to include the totality of the information needed to formulate and validate an effective strategy for cancer prevention and treatment." - Anonymous Online Contributor

Unverified Answer

Can cancer be cured?

"Although many tumors can be treated, there are not specific cancer treatments that cure all tumors. More work on improving cancer treatments as a whole, rather than the specific treatment, is now needed." - Anonymous Online Contributor

Unverified Answer

What is cancer?

"Cancer is a disease that is characterized by uncontrolled rapid growth of abnormal cells within a healthy tissue. Cancer causes a wide range of disorders, including but not limited to tissue damage, organ failure, and death." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of thor-707?

"These side-effects occurred with almost all patients and may vary with the dosage. In this trial, most of the side effects were mild and most of the reactions were tolerable. The most common reactions included itching. Thor-707-induced itching occurred in a large proportion of patients." - Anonymous Online Contributor

Unverified Answer

Has thor-707 proven to be more effective than a placebo?

"There is not much difference if the patients take thor-607 or thor-707. Thor-707 showed more improvement of disease severity in patients compared with placebo; but more adverse events happened in patients taking thor-707 compared with patients taking thor-607. A randomized controlled trial with larger and longer follow-up period is needed to clarify if thor-707 may be more effective than thor-607." - Anonymous Online Contributor

Unverified Answer

Have there been any new discoveries for treating cancer?

"What has progressed in the treatment of solid tumor is remarkable but it is still on a small scale and should it not be that there is more which we have yet to discover and there should not be the fact that we know what we want to know. Even though there’s no one single treatment yet, there are several things which one can try which are not always the same, nevertheless, if they do not bring a better life to the patient, they would never gain anything, only get a lot of pain and maybe even death from cancer. I do think that if this is not enough, then maybe it is time for us to start thinking about the best way to treat the disease which is happening to be cancer." - Anonymous Online Contributor

Unverified Answer

What does thor-707 usually treat?

"In summary, threonine-containing peptides can reduce the amount and development of tumors and prolong survival time. Moreover, these peptides will inhibit the proliferation of tumor cells and inhibit the growth of tumors; thus, it can be regarded as a new chemotherapeutic drug." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of cancer?

"The incidence of cancer increases with age, but, over and above age, more cancer arises in women and/or in people with some type of genetic predisposition for cancer. Thus, the primary underlying cause, if any, of cancer is sex factor. Over and above sex, people who carry genetic risk factors for cancer are at higher risk of developing cancer and are therefore at an increased risk of developing specific types of cancer, such as breast cancer or colorectal cancer, when compared to people without a known predisposing factor for these types of cancer." - Anonymous Online Contributor

Unverified Answer

How serious can cancer be?

"The seriousness of the disease is dependent on the location and type of cancer. Most severe is the case of cancers in the bones, lung, and liver. The prognosis of those types of cancers is generally poor, and they require prompt intervention by surgeons. Those cancers are likely to have spread at the time of diagnosis, and then become harder to cure than those in the rest of the bodies. The prognosis of cancer can be categorized into 4 stages, and these cancers are much better in the early stages of the disease. Stage I, II, and III cancers that have begun growing can be treated to cure them, but a disease has not set in yet, so it cannot be treated." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Cancer by sharing your contact details with the study coordinator.